George V. Migausky's most recent trade in Regenxbio Inc was a trade of 39,815 Stock Options (Right to Buy) done . Disclosure was reported to the exchange on May 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | George V. Migausky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 39,815 | 39,815 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | George V. Migausky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 7,768 | 19,054 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | George V. Migausky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 16,188 | 137,251 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | George V. Migausky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 7,600 | 7,600 | - | - | Stock Option (right to buy) | |
| Regenxbio Inc | George V. Migausky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 24,454 | 24,454 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | George V. Migausky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 4,790 | 11,286 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | George V. Migausky | Director | 02 Apr 2024 | 11,255 | 121,063 (0%) | 0% | 0 | Common Stock | ||
| Immunovant Inc | George V. Migausky | Director | 02 Apr 2024 | 4,690 | 4,690 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | V. George Migausky | Director | 01 Dec 2023 | 5,022 | 109,808 (0%) | 0% | 40.5 | 203,190 | Common Stock | |
| Immunovant Inc | V. George Migausky | Director | 01 Dec 2023 | 4,200 | 118,308 (0%) | 0% | 38.8 | 162,918 | Common Stock | |
| Immunovant Inc | V. George Migausky | Director | 01 Dec 2023 | 3,478 | 114,830 (0%) | 0% | 39.8 | 138,459 | Common Stock | |
| Regenxbio Inc | George V. Migausky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 17,892 | 17,892 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | George V. Migausky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 3,486 | 6,496 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | George V. Migausky | Director | 12 Apr 2023 | 16,260 | 16,260 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | George V. Migausky | Director | 12 Apr 2023 | 12,523 | 122,508 (0%) | 0% | 0 | Common Stock | ||
| Immunovant Inc | George V. Migausky | Director | 17 Aug 2022 | 31,668 | 31,668 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | George V. Migausky | Director | 17 Aug 2022 | 21,059 | 109,985 (0%) | 0% | 0 | Common Stock | ||
| Regenxbio Inc | George V. Migausky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 15,324 | 15,324 | - | - | Stock Option (Right to Buy) | |
| Regenxbio Inc | George V. Migausky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 3,010 | 3,010 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | George V. Migausky | Director | 10 Jan 2022 | 71,492 | 131,792 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | George V. Migausky | Director | 10 Jan 2022 | 21,726 | 88,926 (0%) | 0% | 0 | Common Stock | ||
| Regenxbio Inc | George V. Migausky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Immunovant Inc | George V. Migausky | Director | 20 Aug 2021 | 7,000 | 67,200 (0%) | 0% | 7.7 | 53,550 | Common Stock | |
| Immunovant Inc | George V. Migausky | Director | 19 Mar 2021 | 23,300 | 23,300 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | George V. Migausky | Director | 19 Mar 2021 | 15,500 | 60,200 (0%) | 0% | 0 | Common Stock |